ATE412182T1 - Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome - Google Patents

Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome

Info

Publication number
ATE412182T1
ATE412182T1 AT04741160T AT04741160T ATE412182T1 AT E412182 T1 ATE412182 T1 AT E412182T1 AT 04741160 T AT04741160 T AT 04741160T AT 04741160 T AT04741160 T AT 04741160T AT E412182 T1 ATE412182 T1 AT E412182T1
Authority
AT
Austria
Prior art keywords
prn3
ileu
elastatse
proteinase
leukocyte
Prior art date
Application number
AT04741160T
Other languages
English (en)
Inventor
Michael Tacke
Peter Berndt
Marie-Luise Hagmann
Johann Karl
Hanno Langen
Stefan Palme
Markus Roessler
Wolfgang Rollinger
Werner Zolg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE412182T1 publication Critical patent/ATE412182T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT04741160T 2003-07-21 2004-07-20 Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome ATE412182T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03015695 2003-07-21

Publications (1)

Publication Number Publication Date
ATE412182T1 true ATE412182T1 (de) 2008-11-15

Family

ID=34130019

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04741160T ATE412182T1 (de) 2003-07-21 2004-07-20 Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome

Country Status (6)

Country Link
US (1) US20060177880A1 (de)
EP (1) EP1649289B1 (de)
AT (1) ATE412182T1 (de)
DE (1) DE602004017317D1 (de)
ES (1) ES2316997T3 (de)
WO (1) WO2005015219A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019368A2 (fr) * 2007-07-19 2009-02-12 bioMérieux Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919062B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
CN102165075A (zh) * 2008-07-18 2011-08-24 奥洁克公司 用于检测和治疗结肠直肠癌的组合物
EP2758421A4 (de) * 2011-09-23 2015-03-25 Univ Texas Zusammensetzungen und verfahren in zusammenhang mit gewebetargeting
CA3066738A1 (en) * 2017-06-15 2018-12-20 The University Of Chicago Methods and compositions for treating cancer
US12516307B2 (en) 2020-08-18 2026-01-06 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins

Also Published As

Publication number Publication date
EP1649289A1 (de) 2006-04-26
DE602004017317D1 (de) 2008-12-04
WO2005015219A1 (en) 2005-02-17
US20060177880A1 (en) 2006-08-10
ES2316997T3 (es) 2009-04-16
EP1649289B1 (de) 2008-10-22

Similar Documents

Publication Publication Date Title
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
DE60223561D1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
ATE554389T1 (de) Apex als marker für lungenkrebs
ATE412182T1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE513216T1 (de) Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
DE602005013998D1 (de) Verfahren und reagenzien zur erkennung von melanomen
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
ATE393393T1 (de) Verwendung des proteins spee als marker für brustkrebs
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales
ATE410691T1 (de) Verwendung des proteins proteasome aktivator untereinheit 3 als marker für kolorektale karzinome
ATE418737T1 (de) Verwendung des proteins spermidinsynthase (spee) als marker für kolorektalkarzinom
DE602005014659D1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
NO20061215L (no) Fremgangsmate for identifisering av IRS-proteinkinase-inbibitorer eller -agonister

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1649289

Country of ref document: EP